ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO939

Persistence of Antibody Response to COVID-19 Vaccine in Peritoneal Dialysis (PD) Patients: A Single Center Study

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Rahim, Shab E Gul, Weill Cornell Medicine, New York, New York, United States
  • Tummalapalli, Sri Lekha, Weill Cornell Medicine, New York, New York, United States
  • Stryjniak, Gabriel J., Weill Cornell Medicine, New York, New York, United States
  • Gerardine, Supriya, Weill Cornell Medicine, New York, New York, United States
  • Srivatana, Vesh, Rogosin Institute, New York, New York, United States
Background

Published studies on the response to COVID-19 vaccination are primarily focused on hemodialysis. We studied the humoral response to the COVID-19 vaccine in a PD population over a 6 month follow-up period.

Methods

In a retrospective single-center study, we assessed response to COVID-19 vaccination in patients on PD at 4 weeks, 3 months and 6 months after completing the full vaccination series. Response was measured via semiquantitative COVID-19 spike protein total antibody (IgG) level using a chemiluminescent sandwich immunoassay. Antibody (Ab) titers <1 were categorized as no response, 1 to <20 as intermediate, and >20 as high response. Chi-squared tests for categorical variables and unadjusted linear regression for continuous variables were used to compare characteristics among responders vs non-responders.

Results

Of 119 patients on PD who received COVID-19 vaccine as of December 2021, 108/119 (91%) had a positive Ab response and 11/119 (9%) had no response. A total of 37% had an intermediate and 53.7% had a high response. Positive COVID-19 serology prior to vaccination (p= 0.010) as well as type of vaccine (p=0.032) were associated with higher Ab response in univariate analyses. Other factors were not statistically significantly associated with Ab response. Among the 73 participants with Ab levels at all timepoints, at 4 weeks, 11 (15%) had no Ab response, 19 (26%) intermediate, and 43 (59%) high response. At 3 months, 12 (16%) of participants had no Ab response, 27 (37%) intermediate, and 34 (47%) high response. At 6 months, 12 (16%) of participants had no Ab response, 38 (52%) intermediate, and 23 (32%) high response.

Conclusion

Most PD patients developed a positive Ab response to the COVID-19 vaccine. Positive COVID-19 serology prior to vaccination and the type of vaccine received were associated with higher Ab response. Our data suggests promising COVID-19 vaccine response among PD patients.

Characteristics of Patients Receiving Peritoneal Dialysis by COVID-19 Antibody Response